{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:09:55Z","timestamp":1794740995881,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development program of an aesthetic neuromodulator in glabellar lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the use of DAXI (40U) up to 3 treatments for moderate or severe glabellar lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Eligible subjects rolled over from the placebo-controlled trials (<jats:italic toggle=\"yes\">n<\/jats:italic> = 477) or were de novo (<jats:italic toggle=\"yes\">n<\/jats:italic> = 2,214) and received 1 to 3 treatments over a maximum of 84 weeks. Safety and efficacy were evaluated at least every 4 weeks up to Week 36 (Treatments 1 and 2) and Week 12 (Treatment 3). Select subjects could be retreated after Week 12 if glabellar lines returned to baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Safety results are reported for 2,691 subjects, of which 882 received a second treatment and 568 a third. Treatment-related adverse events (AEs) occurred in 17.8% of subjects, which were generally mild and resolved. No serious AEs were treatment-related. Eyelid ptosis occurred in 0.9% of treatments. Adverse events were consistent across treatments and no new safety signals were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The safety of DAXI in this large open-label safety study confirms the findings from the pivotal Phase 3 trials, providing reassurance in its overall safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002463","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T22:02:57Z","timestamp":1597010577000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":27,"title":["A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study"],"prefix":"10.1097","volume":"47","author":[{"given":"Jeremy B.","family":"Green","sequence":"first","affiliation":[{"name":"Skin Associates of South Florida, Coral Gables, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Mariwalla","sequence":"additional","affiliation":[{"name":"Mariwalla Dermatology, West Islip, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Coleman","sequence":"additional","affiliation":[{"name":"Etre Cosmetic Dermatology and Laser Center, New Orleans, Louisiana;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynis","family":"Ablon","sequence":"additional","affiliation":[{"name":"Ablon Skin Institute & Research Center, Manhattan Beach, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Weinkle","sequence":"additional","affiliation":[{"name":"University of South Florida, Tampa and Private Practice, Bradenton, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Vitarella","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman G.","family":"Rubio","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc., Newark, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042728-200305000-00003","article-title":"Social implications of hyperfunctional facial lines","volume":"29","author":"Finn","year":"2003","journal-title":"Dermatol Surg"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00266-016-0682-1","article-title":"Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis","volume":"40","author":"Jia","year":"2016","journal-title":"Aesthet Plast Surg"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/DSS.0000000000002531","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study","volume":"47","author":"Fabi","year":"2021","journal-title":"Dermatol Surg"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA in the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/PRS.0b013e3181b5641b","article-title":"Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study","volume":"124","author":"Kane","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"key":"R14-20250731","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/dsu.12100","article-title":"Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines","volume":"39","author":"Carruthers","year":"2013","journal-title":"Dermatol Surg"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dsu.12160","article-title":"A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint","volume":"39","author":"Hanke","year":"2013","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:12:18Z","timestamp":1753999938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002463","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]}}}